Actively Recruiting

Phase Not Applicable
Age: 18Years - 39Years
FEMALE
NCT04804332

Removal of Intrauterine Retained Products of Conception (RPOC) After Miscarriage Guided by Hysteroscopy Trial. A Randomized Controlled Trial.

Led by University Hospital, Ghent · Updated on 2024-05-14

244

Participants Needed

1

Research Sites

337 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Ghent

Lead Sponsor

M

Medtronic

Collaborating Sponsor

AI-Summary

What this Trial Is About

Rationale: Elective immediate dilation and curettage (D\&C) for miscarriage is associated with the occurrence of intrauterine adhesions (IUA). IUAs may be associated with subsequent subfertility and premature birth. Recent studies have shown that in women with miscarriage, medical treatment (misoprostol/mifepristone) is an effective alternative for curettage. A problem with medication and expectant management is that after initial treatment, sonographic findings during follow-up frequently show incomplete evacuation of uterine retained products of conception (RPOC), which often lead to additional interventions or expectant time-consuming management limiting the benefits of medical treatment. Objective: To assess, in women with a wish for immediate future pregnancy and RPOC after non-surgical management of a miscarriage, as diagnosed with sonography, the effects of operative hysteroscopy versus expectant management. Study design: Multicenter randomized clinical trial. Study population: Patients after non-surgical management of a miscarriage with sonographic evidence of RPOC at the follow-up visit 6 weeks after initial treatment and wish for immediate (within 6 months) future pregnancy. Intervention: operative hysteroscopy versus expectant management. Main study parameters/endpoints: The primary outcome is time to next pregnancy, as substantiated by a positive urinary or serum hCG test. Secondary outcomes are Quality of Life (QOL) scores assessed with the SF-36, HADS and EQ-5D-5L, the need for additional and/or unscheduled treatments and/or visits and complications. Furthermore, data on the course of pregnancy - including miscarriage, ectopic pregnancy and live birth - are documented in those women who have an ongoing pregnancy after randomization during the study follow up period. In addition, iMTA PCQ questionnaires and health-costs are measured in all patients to perform a cost-effectiveness analysis. A total of 244 (122 per arm) women will be sufficient to answer the questions on the primary endpoint. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Women participating in the study will be asked to fill out questionnaires at baseline, 8 weeks and 6 months after randomization. We don not expect specific risks as a result of either the intervention or expectant management.

CONDITIONS

Official Title

Removal of Intrauterine Retained Products of Conception (RPOC) After Miscarriage Guided by Hysteroscopy Trial. A Randomized Controlled Trial.

Who Can Participate

Age: 18Years - 39Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients after first trimester miscarriage treated non-surgically with sonographic evidence for the presence of RPOC at follow-up visit after 6 weeks (± 1 week)
  • Immediate future pregnancy wish
  • Willingness to give informed consent
Not Eligible

You will not qualify if you...

  • Women aged below 18 years
  • Women aged over 39 years
  • Women not wanting to achieve pregnancy within the first 6 months after non-surgical treatment for miscarriage
  • History of repeated miscarriage defined as 3 or more consecutive pregnancy losses before 20 weeks of pregnancy duration
  • Untreated and/or untreatable subfertility
  • Severe uterine bleeding needing acute medical intervention
  • Severe abdominal pain needing acute medical intervention
  • Fever (> 38.5° Celsius) or sepsis requiring antibiotic treatment
  • Contraindication for (office) operative hysteroscopy
  • Failed non-surgical management for miscarriage with intact gestational sac
  • Congenital uterine anomaly
  • Known cervical stenosis making safe uterine access impossible
  • Visual or pathological evidence of malignancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ghent University Hospital

Ghent, Belgium, 9000

Actively Recruiting

Loading map...

Research Team

E

Eline Meireson

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here